Biotech ETFs were among the best entertainers in 2014 and the spotlight has stayed focused on this corner of the medicinal services showcase as speculators keep on seeking out lucrative development opportunities. At the same time in the matter of making presentation, contrasted with some different corners of the business sector, there just hasn’t been the same level of granularity among the ETFs that are intended to give access to this fragment of the health awareness industry.
Twenty three UK biotechnology tasks will impart £20 million from the Industrial Biotechnology Catalyst rivalry reserve. Acquainted in January 2014 with help coordinated effort between UK specialists and the developing mechanical biotechnology area, Business Secretary Vince Cable yesterday reported the financing beneficiaries.
Social insurance stocks fell extensively on Wall Street on Wednesday, with the area seeing a general decay of 0.3%.
Insights about some real gainers from healthcare segment, amid Thursday’s exchange are depicted underneath:
Biocept, Inc. (NASDAQ:BIOC)’s shares skyrocketed 10.07% and led the share to close at $1.53, as a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, recently declared the pricing of an underwritten public offering of 8,000,000 shares of its ordinary stock and warrants to purchase up to an aggregate of 8,000,000 shares of its ordinary stock at a combined offering price of $1.25. The warrants will have a per share exercise price of $1.56, are exercisable right away and will expire five years from the date of issuance. The gross proceeds to Biocept from this offering are predictable to be about $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Biocept has granted the underwriters a 45-day option to purchase up to an additional 1,200,000 shares of ordinary stock and/or 1,200,000 additional warrants to cover over-allotments, if any. The offering is closed on February 13, 2015, subject to customary closing conditions.
Aegis Capital Corp. and Feltl and Company, Inc. are acting as joint book-running managers for the offering.
Biocept, Inc. (NASDAQ:BIOC), headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients’ tumors to physicians using its proprietary technology platform to assist improve individual patient treatment.
Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), jumped nearly 8.50% and closed at $13.02, soon after a biotechnology company specializing in the characterization and engineering of complex drugs, recently declared that its presentation at Cowen and Company’s 35th Annual Health Care Conference will be webcast on Tuesday, March 3 at 10:40 a.m. ET.
The audio webcast of the presentation will be accessible live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website about one hour after the event and will be accessible for two weeks following the presentation.
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
Signal Genetics, Inc. (NASDAQ:SGNL), surged 8.40% to close at $2.84, soon after a commercial stage molecular diagnostic company, molecular diagnostic company focused on providing innovative diagnostic services that assist physicians make better-informed decisions concerning the care of their patients suffering from cancer, recently declared the pricing of an underwritten public offering of 3,214,285 shares of its ordinary stock at an offering price of $2.80 per share. The gross proceeds to Signal from this offering are predictable to be about $9,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Signal has granted the underwriters a 45-day option to purchase up to an additional 482,142 shares of ordinary stock to cover over-allotments, if any. The offering is predictable to close on February 20, 2015, subject to customary closing conditions.
Aegis Capital Corp. and Chardan Capital Markets, LLC are acting as joint book-running managers for the offering.
Signal Genetics, Inc. (NASDAQ:SGNL), headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that assist physicians make better-informed decisions concerning the care of their patients suffering from cancer. Signal’s mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions.
Shares of the Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), gained 7.17% & closed at $2.39, soon after a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, declared that Eric Bjerkholt, Executive Vice President of Corporate Development and Finance and Chief Financial Officer of Sunesis, will present at the 2015 RBC Capital Markets’ Global Healthcare Conference on Wednesday, February 25th at 11:30 AM Eastern Time at the New York Palace Hotel in New York City.
A live webcast of the presentation will be accessible on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the “Calendar of Events” page in the Investors and Media section of the Sunesis website for two weeks.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly practiced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
